BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsFDA / regulatory

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of

Related news

ARWRArrowhead Pharmaceuticals2026-04-24 10:39 EST

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

CRNXCrinetics Pharmaceuticals2026-04-27 21:13 EST

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

ETONEton Pharmaceuticals2026-07-29 10:50 EST

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

ETONEton Pharmaceuticals2026-05-19 20:30 EST

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

KRYSKrystal Biotech2026-05-18 12:00 EST

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

RAREUltragenyx Pharmaceutical2026-04-02 12:30 EST

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

BIIBBiogen2026-07-13 21:38 EST

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

PHVSPharvaris2026-07-06 10:50 EST

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

ARWRArrowhead Pharmaceuticals2026-08-03 20:30 EST

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ARWRArrowhead Pharmaceuticals2026-07-27 11:30 EST

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Stock data

Close
85.83 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States